Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., said the European Medicines Agency accepted the marketing authorization application filing for Nuedexta (dextromethorphan HBr and quinidine sulfate) to treat pseudobulbar affect. Nuedexta gained approval in the U.S. in October 2010.